@article{CCO1353,
author = {Enrico Balleari and Lisette Del Corso},
title = {High-dose recombinant human erythropoietin for “low-risk” myelodysplastic patients: is more better?},
journal = {Chinese Clinical Oncology},
volume = {1},
number = {2},
year = {2013},
keywords = {},
abstract = {In present issue of the Journal Azzarà and Colleagues describe a retrospective series of 133 anemic patients with low/intermediate-1 risk myelodysplastic syndromes (MDS) treated with high-dose (40,000 IU twice a week) of alpha recombinant human erythropoietin (alpha-rHuEPO) (1).},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/1353}
}